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404ercutaneous coronary intervention (PCI) is the revasculariza-
ion strategy of choice for many patients with coronary heart
isease. Outside of clinical research trials, current U.S. and
uropean guidelines recommend clinical follow-up after PCI,
ith angiography reserved to evaluate patients who have recur-
ent symptoms or objective evidence of myocardial ischemia
1,2). This is based on the knowledge that ischemic symptoms
orrelate with an increased risk of adverse clinical outcomes
3,4) and that revascularization of the ischemic culprit lesions
an improve both functional status and subsequent patient
utcome (4–6). In contrast, coronary lesions that do not
roduce ischemia typically fail to benefit from revascularization
ompared with continued optimal medical therapy alone (7–9).
onetheless, routine 6-month angiography is still performed
n selected centers in an effort to identify angiographic signif-
cant stenoses that have not resulted in ischemic signs or
symptoms (10), despite the added
cost and small associated proce-
dural risk (11–14).
Numerous trials of balloon an-
gioplasty, bare-metal stents (BMS),
and drug-eluting stents (DES)
have shown that patients who un-
dergo mandatory angiographic
follow-up tend to receive signifi-
cantly more repeat revasculariza-
tion procedures than those having
clinical follow-up alone (10,15–18),
via a phenomenon known as the
“oculostenotic” reflex (19,20). It
is unknown how routine angio-
graphic follow-up affects long-
term clinical outcomes—whether
the associated increase in repeat
revascularization provides any
clinical benefit by reducing the
subsequent incidence of myocar-
dial infarction (MI) or mortality
uring longer-term observation (10,18,21) or is perhaps even
armful.
We therefore performed a patient-level meta-analysis on the
ombined TAXUS IV and V (de novo [DN]) and ATLAS
Workhorse [WH]) trials to compare the clinical outcomes of
atients assigned to routine angiographic follow-up with those
ssigned to clinical follow-up alone. We also performed a
andmark analysis of patients with angiographically intermedi-
te, nonischemic lesions to assess any long-term clinical benefit
mong those who were or were not revascularized at the time
f angiographic follow-up.
ethods
tudy population. The patient-level databases of the pro-
bbreviations
nd Acronyms
MS  bare-metal stent(s)
EC  clinical events
ommittee
ES  drug-eluting stent(s)
N  de novo
S  diameter stenosis
I  myocardial infarction
CI  percutaneous
oronary intervention
ES  paclitaxel-eluting
tent(s)
CA  quantitative coronary
ngiography
LR  target lesion
evascularization
VR  target vessel
evascularization
H  workhorsepective, randomized, double-blind TAXUS IV (n 1,314; l-year follow-up) (22,23) and TAXUS V-DN (n  1,156;
-year follow-up) (24) trials for the TAXUS Express stent
ere pooled with the TAXUS Liberté stent arm of the
istorically controlled TAXUS ATLAS-WH (n  871,
-year follow-up) trial (25), in a patient-level meta-analysis
total n  3,341). These studies comprise the pivotal trials for
he TAXUS Express and TAXUS Liberté paclitaxel-eluting
tents (PES) (Boston Scientific, Natick, Massachusetts). An-
iographic follow-up was prespecified in a subset of TAXUS
V and ATLAS-WH patients and in all TAXUS V-DN
atients (total n 2,431); clinical-only follow-up was assigned
n the other 910 patients.
nd points and deﬁnitions. In-segment percentage diameter
tenosis (DS) was defined as percentage stenosis within the
nalysis segment that included the 5-mm proximal to 5-mm
istal margins of the stent. Adverse cardiac events (cardiac
eath or MI, target lesion revascularization [TLR], target
essel revascularization [TVR], nontarget lesion TVR, and
cademic Research Consortium definite/probable stent
hrombosis [26]) were adjudicated by independent clinical
vents committees (CECs) during the course of each trial. The
LR was adjudicated as ischemia-driven (clinically driven) if
he target lesion was 70% DS by quantitative coronary
ngiography (QCA) or for DS between 50% and 70% if
he CEC determined there was objective evidence of ischemia.
ite-reported TLR (i.e., nonclinically driven TLR, not con-
rmed as ischemic-driven by the CEC) was also analyzed.
For the landmark analysis, any revascularization occurring
14 days after routine follow-up angiography was excluded as
long-term end point to avoid including staged revasculariza-
ion procedures as long-term events. Other end points were
ncluded from the date of angiographic follow-up.
tatistical analysis. Analysis of the intent-to-treat sample
as conducted with SAS System Software, version 8.0 or
igher (SAS Institute, Cary, North Carolina). Categorical
ariables were compared by chi-square or Fisher exact test.
ontinuous variables were described as mean  SD and
ere compared with analysis of variance. Time-to-event
ata were reported and displayed as Kaplan-Meier estimates
ith comparisons between groups by the log-rank test. The
ox proportional hazard model was used to assess long-
erm clinical outcomes.
To minimize bias due to baseline differences between the
outine angiographic (which included the more complex
AXUS V patients) and clinical follow-up groups, Greedy
:1 matching was performed with a propensity score gen-
rated by a logistic regression model. Covariates for this
odel were selected if they differed significantly between
he 2 groups or were clinically important; colinearity and
esults of the goodness-of-fit test were also considered in
election. The covariates included binary variables (sex, prior
oronary artery bypass graft surgery, diabetes, hypertension,
yperlipidemia, smoking, history of coronary artery disease,eft anterior descending artery location, tortuosity, multiple
s
H
(
l
m
o
y
w
l
i
s
i
l
e
R
P
T
7
a
w
n
a
b
t
f
E
A
a
9
t
g
w
p
P
H
m
c
c
a
(
1
B
0
t
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 4 , 2 0 1 0 Uchida et al.
A P R I L 2 0 1 0 : 4 0 3 – 1 1 No Benefit of Routine Follow-Up Angiography in PCI
405tents, and American College of Cardiology/American
eart Association B2/C lesions) and continuous variables
age, baseline reference vessel diameter [QCA], and lesion
ength [QCA]). A total of 13 patients were unable to be
atched, due to missing baseline values.
Annualized hazard rates were calculated for cardiac death
r MI, TVR, TLR, and nontarget lesion TVR (for 0 to 1
ear and 1 to 5 years) with the person-time method and
ere expressed as the event rate/100 patient-years (equiva-
ent to event percentage/patient/year). To determine the
mpact of stenosis on TLR in the 2 follow-up cohorts,
tenosis was divided into 3 categories: mild (40% DS),
ntermediate (40% to 70%), and severe (70%). A
andmark analysis was performed on patients who were
vent-free up until the 9-month follow-up.
esults
atient characteristics. Patients were pooled from the
AXUS IV, V-DN, and ATLAS-WH trials (n  3,341);
2% had been randomly assigned to receive mandated
ngiographic follow-up (BMS n  936; PES n  1,495),
hereas 28% were assigned to clinical follow-up only (BMS
 295; PES n  615). Groups of routine angiographic
Table 1. Clinical and Angiographic Characteristics in
Unadjusted Pati
Follow-Up*
Clinical
(n  910)
Angio
(n 
Age (yrs) 62.1 11.0 62.6
Female 27.6 3
Prior PCI 32.0 3
Prior CABG 6.8 1
Unstable angina 31.5 3
Stable angina 55.7 5
Diabetes mellitus 22.9 2
Hypertension 69.2 7
Hyperlipidemia 69.9 7
Smoking 24.9 2
History of coronary artery disease 54.6 5
Renal disease 3.4
Baseline lesion characteristics
RVD (QCA), (mm) 2.7 0.5 2.7
Lesion length (QCA), (mm) 12.8 5.6 15.9
QCA DS 67.0 11.0 67.9
Multiple stents 6.9 1
Ejection fraction 55.5 9.9 55.3
AHA/ACC type B2/C lesions 56.0 7
Values aremean SDor%. The p value for continuous data fromanaly
patients receiving either bare-metal or paclitaxel-eluting stent.
ACC/AHA American College of Cardiology/American Heart AssocPCI percutaneous coronary intervention; QCA quantitative coronary angnd clinical-only follow-up patients were matched on the
asis of propensity score, to minimize any imbalances in
heir baseline characteristics (n  897 patients from each
ollow-up group; Table 1).
ffect of routine angiographic follow-up on clinical events.
s shown in Figure 1, the rates of TLR were similar in the
ngiographic and clinical follow-up cohorts (Fig. 1A) until
-month protocol-mandated angiography, at which time
he rate of overall TLR increased abruptly in the angio-
raphic group. After the close of the angiographic follow-up
indow, the rates of ischemic TLR in the 2 cohorts again
aralleled each other. Similar results were found when
ES-treated patients were analyzed separately (Fig. 1C).
owever, in the BMS-treated patient cohort, there were
ore early clinically driven TLRs than in the PES-treated
ohort. This might have resulted in there being no statisti-
ally significant difference between the clinical-only and
ngiographic follow-up groups in the BMS-treated cohort
Fig. 1B). Due to lower rates of TLR in PES (angiographic
5.9% vs. clinical-only 7.4%, p  0.001) compared with
MS (23.6% angiographic vs. 18.9% clinical-only, p 
.17), angiographic follow-up had greater relative impact on
he overall TLR rates in PES-treated patients (odds ratio
justed and Propensity-Matched Cohorts
pulation Propensity-Matched Patient Population
p Value
Follow-Up*
p Value
c
)
Clinical
(n  897)
Angiographic
(n  897)
0.30 62.1 11.0 61.9 11.1 0.64
0.13 27.4 26.8 0.79
0.97 32.0 30.9 0.65
0.001 6.9 6.9 0.99
0.48 31.4 31.1 0.92
0.99 56.0 58.0 0.42
0.002 22.7 22.4 0.91
0.02 69.4 69.1 0.92
0.44 69.9 70.9 0.68
0.51 22.2 23.9 0.43
0.049 54.7 56.6 0.45
0.18 3.3 4.4 0.32
0.91 2.7 0.5 2.8 0.5 0.22
0.001 12.9 5.6 12.9 5.9 0.83
0.04 66.9 10.9 67.1 11.4 0.72
0.001 5.2 5.2 0.99
0.72 55.5 10.0 55.6 9.6 0.87
0.01 56.1 57.0 0.74
riance. The p value for categorical data from chi-square test. *Includes
S diameter stenosis; CABG coronary artery bypass graft surgery;Unad
ent Po
graphi
2,431
 10.9
0.2
2.0
0.5
2.8
5.7
8.2
3.2
1.2
3.7
8.4
4.5
 0.5
 8.2
 11.5
9.7
 10.0
2.0
sis of va
iation; Diography; RVD reference vessel diameter.
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40695% confidence interval]: PES 2.37 [1.60 to 3.53] vs. BMS
.34 [0.90 to 2.01], p  0.048).
The higher rates of overall TLR in the routine angiography
ohort were not associated with any significant difference in the
ubsequent combined end point of cardiac death or MI in the
verall patient population or in either BMS- or PES-treated
atients (Figs. 2A to 2C). Similar results were found when
utcomes were analyzed as annualized hazard rates (Table 2).
ther than the previously noted significant difference in TLR
nd TVR between 9 months and 1 year, there was no
ignificant increase or decrease in either measure of repeat
Figure 1. Cumulative Rate of TLR in Patients With Angiographic or
Clinical-Only Follow-Up
Target lesion revascularization (TLR) is increased in patients with routine
angiographic compared with clinical-only follow-up, for the propensity-
matched complete group (A) and the bare-metal stent (BMS) (B) and
paclitaxel-eluting stent (PES) (C) cohorts. OR  odds ratio.evascularization from 1 through 5 years. A borderline increasen nontarget lesion TVR at 1 year was also present, with no
ignificant differences in the rate of cardiac death or MI or in
cademic Research Consortium definite/probable stent
hrombosis between the 2 follow-up strategies during the first
r subsequent years.
vidence for differential oculostenotic treatment of intermediate
esions. The influence of the follow-up strategy on the
elationship between baseline %DS and overall TLR be-
ween 90 and 300 days is shown for the unadjusted and
ropensity-matched patient populations (Fig. 3). Few pa-
ients with mild lesions (%DS 40%) had repeat revascu-
Figure 2. Cumulative Rate of Cardiac Death or MI in Patients With
Angiographic or Clinical-Only Follow-Up
There was no statistically signiﬁcant difference in rate of cardiac death or
myocardial infarction (MI) between the propensity-matched routine angio-
graphic and clinical-only follow-up cohorts for the complete group (A) or
the BMS (B) and PES (C) cohorts. Abbreviations as in Figure 1.
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407arization, regardless of the type of follow-up. In contrast,
he routine angiography group had a much higher rate of
evascularization for intermediate lesions (%DS 40% and
70% by QCA). For severe lesions (70% DS by QCA),
he rates of TLR were again largely similar in patients with
ngiographic versus only clinical follow-up. Thus in the
ropensity-matched patient population, the 5.7% overall
ifference in absolute TLR rates between the 2 follow-up
roups (angiographic 10.4% vs. clinical 4.7%) was due
ostly (65%) to revascularization of lesions in the interme-
iate (40 to 70% DS) range, with the remaining 35% of
he difference found in lesions at the lower end of severe
70% DS) stenosis.
utcomes in patients with revascularized intermediate lesions.
mong 316 patients in whom intermediate lesions were found
n the 9-month protocol-mandated angiogram, 63 (19.9%)
ere adjudicated by the CEC to have had ischemia-driven
LR, and 45 (14.2%) were adjudicated to have had angio-
raphically driven TLR without evidence of ischemia. An
dditional 208 patients with intermediate lesions were not
reated at the time of 9-month angiographic follow-up; a
omparison group (n  1,142) of nontreated patients with
ild lesions (40% DS by QCA) was also identified.
As shown in Table 3, the long-term rate of cardiac death or
I was higher in the intermediate lesion patients, judged to
ave ischemia-driven repeat revascularization, than in those
ith angiographically driven TLR or no TLR (11.5%, 2.2%,
Table 2. Annualized Hazard Rates for Propensity-Matched Patients Assigne
0–1 Year
Annualized Hazard Rate, % (95% CI)
Clinical Follow-Up
Angiographic
Follow-Up
Hazard Rati
(95% CI)
Overall n  897 n  897
Cardiac death or MI 4.9 (3.4–6.4) 4.4 (3.0–5.9) 0.9 (0.6–1.4
TVR 8.5 (6.5–10.5) 18.3 (15.4–21.2) 2.2 (1.6–2.9
TLR 6.7 (5.0–8.4) 14.2 (11.7–16.8) 2.1 (1.6–2.9
Non-TL TVR 2.7 (1.6–3.8) 4.6 (3.2–6.1) 1.7 (1.0–2.8
BMS n  292 n  292
Cardiac death or MI 7.3 (4.1–10.5) 4.7 (2.1–7.2) 0.6 (0.3–1.3
TVR 16.9 (11.9–21.9) 25.3 (19.2–31.4) 1.5 (1.0–2.2
TLR 15.3 (10.6–20.0) 21.5 (15.9–27.1) 1.4 (0.9–2.1
Non-TL TVR 3.5 (1.3–5.7) 4.6 (2.1–7.1) 1.3 (0.6–3.0
PES n  605 n  605
Cardiac death or MI 3.8 (2.2–5.4) 4.3 (2.6–6.0) 1.1 (0.6–2.0
TVR 4.8 (3.0–6.5) 15.1 (11.9–18.3) 3.2 (2.1–4.9
TLR 2.9 (1.5–4.2) 10.8 (8.1–13.5) 3.8 (2.2–6.5
Non-TL TVR 2.4 (1.1–3.6) 4.6 (2.9–6.4) 2.0 (1.0–3.8
Rate/100 patient-years.
BMS  bare-metal stent(s); CI  confidence interval; MI  myocardial infarction; Non-TL TVR 
revascularization; TVR target vessel revascularization.nd 5.2%, respectively). Similar results were found in each creatment arm (BMS or PES). Although the difference is not
tatistically significant, due to the small sample size, the
schemia-driven group had more diabetic patients (34.9% [22
f 63]) than either the angiographically driven (22.2% [10 of
5]) or untreated (23.1% [48 of 208]) groups. Also, the mean
DS in the ischemia-driven group (61.52  5.23) was higher
han that of the angiographically driven (55.73  6.68) and
ntreated (50.12 7.97) patient groups. These findings might
rovide an explanation for the apparent increase in cardiac
eath and MI in the ischemia-driven, intermediate lesion
roup.
The untreated intermediate lesion group tended to have
ore subsequent TLRs than in the group with nonischemic
ngiographically driven TLR (17.0% and 7.0%, respectively,
 0.08) (Fig. 4). Accordingly, 83% of patients with
ntermediate lesions and no clinical ischemia did not require
LR during the follow-up period. In this regard, the numer-
cal increase in the long-term rates of subsequent TLR of
ntermediate lesions was not significantly different for the PES
roup (angiography driven 10.0% vs. untreated 15.7%,
 0.53) or the BMS group (4.0% vs. 17.9%, p  0.08).
iscussion
he results of this study confirm that patients who are
ssigned to routine angiographic follow-up in clinical stud-
es of DES undergo more TLR than patients assigned to
linical Versus Angiographic Follow-Up
>1–5 Years
Annualized Hazard Rate, % (95% CI)
p Value Clinical Follow-Up
Angiographic
Follow-Up
Hazard Ratio
(95% CI) p Value
n  873 n  862
0.66 1.2 (0.8–1.6) 1.5 (1.0–2.0) 1.3 (0.8–2.0) 0.36
0.001 3.1 (2.4–3.8) 3.5 (2.7–4.2) 1.1 (0.8–1.5) 0.50
0.001 1.5 (1.0–2.0) 2.0 (1.4–2.5) 1.3 (0.9–2.0) 0.23
0.04 1.8 (1.3–2.3) 1.8 (1.2–2.3) 1.0 (0.6–1.5) 0.88
n  279 n  283
0.21 0.9 (0.3–1.4) 1.0 (0.4–1.7) 1.1 (0.4–2.8) 0.86
0.04 3.7 (2.5–4.9) 2.7 (1.6–3.8) 0.7 (0.4–1.2) 0.24
0.10 1.7 (0.9–2.5) 1.5 (0.7–2.3) 0.9 (0.4–1.8) 0.69
0.52 2.2 (1.3–3.1) 1.2 (0.5–2.0) 0.6 (0.3–1.2) 0.14
n  590 n  583
0.65 1.4 (0.8–2.0) 1.8 (1.1–2.5) 1.3 (0.7–2.2) 0.40
0.001 2.8 (1.9–3.6) 4.0 (2.9–5.0) 1.4 (1.0–2.1) 0.09
0.001 1.4 (0.8–2.0) 2.2 (1.5–3.0) 1.6 (0.9–2.8) 0.08
0.04 1.5 (0.9–2.2) 2.1 (1.4–2.8) 1.3 (0.8–2.2) 0.35
arget lesion target vessel revascularization; PES  paclitaxel-eluting stent(s); TLR  target lesiond to C
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408eath or MI during long-term follow-up. Although the
everity of angiographic restenosis was correlated with the
ikelihood of TLR, it was clear that the main effect of
outine angiographic follow-up was to increase the likeli-
ood that a patient with an intermediate restenosis (40 to
70% DS by QCA) but no objective evidence of ischemia
ould undergo repeat revascularization via the so-called
Figure 3. The TLR Rate Between 90 and 300 Days After Stent Implantatio
The largest difference in TLR rates between the follow-up groups was found in
both the unadjusted and propensity-matched cohorts. Abbreviations as in Figu
Table 3. Long-Term Outcomes in Patients With Treated Versus Untreated I
Intermediate Lesions*
Treated
Un
(n
Ischemia-Driven†
(n  63)
Angiography-Driven†
(n  45)
Death 10.1 0.0
Cardiac death 3.3 0.0
MI 8.5 2.2
Cardiac death or MI 11.5 2.2
ST‡ 0.0 0.0
Values are %. Kaplan-Meier event rates at 5 years do not include staged revascularization procedures; p
mediate lesions (40 to70%DS).†Ischemia-driven clinical events committee-adjudicatedTLR; angAbbreviations as in Table 2.culostenotic reflex. This is particularly important, because
nly the minority (22%) of patients with angiographic
estenosis has severe (DS 70%) stenosis most clearly
ssociated with demonstrable myocardial ischemia (21). In
ddition, such intermediate lesions tend to regress over time
2 to 5 years) and generally have a favorable clinical outcome
ith medical therapy alone (27–29).
Function of %DS at Baseline
nts with intermediate lesions (40% to 70% diameter stenosis [DS]) in
ediate Lesions at Follow-Up Angiography
Untreated
Mild Lesions*
(n  1,142)
p Value
d
)
Angiography-Driven
vs. Untreated
Untreated Intermediate
vs. Mild Lesions
5.9 0.13 0.68
2.0 0.25 0.31
1.9 0.92 0.53
2.6 0.43 0.26
0.9 0.50 0.89
were event-free until routine follow-up angiographic visit at 9-months. *Mild lesions (40%DS); inter-
y-driven site-reportedTLR.‡AcademicResearchConsortiumdefinite/probable stent thrombosis (ST).n as a
patienterm
treate
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409The effect of routine follow-up angiography on increasing
epeat revascularization has been documented in previous
tudies (15,16,30). However, the current study is unique in
emonstrating that increased oculostenotic revascularization
fter routine follow-up angiography involved mostly the treat-
ent of intermediate lesions. Subsequent cardiac death or MI
hrough 5 years of follow-up was not reduced in this group
ompared with clinical follow-up alone with limited ischemia-
riven repeat revascularization. Although patients with pre-
mptively treated intermediate lesions after mandated angio-
raphic follow-up did tend to have a slightly lower rate of
dditional TLR than those who were untreated (7% and 17%,
espectively, p  0.08), 83% of untreated patients avoided an
dditional revascularization. In contrast, all of the retreated
atients had at least 1 (and some a second) repeat revascular-
zation. There was no evidence that this increase in preemptive
reatment of intermediate lesions reduced the rate of subse-
uent cardiac death or MI in patients undergoing routine
ngiographic follow-up. Although small routine angiographic
ollow-up cohorts might be ethically justified in trials of new
tents (given the scientific information provided), such proce-
ures should be deferred until after measurement of the
rimary end point to avoid interfering with the assessment of
linical efficacy or clustered in a separate angiographic cohort
rom which the clinical end point is determined.
These findings in patients with intermediate nonischemic
esions do not alter the recommendation that patients with
ecurrent symptoms or evidence of myocardial ischemia
fter PCI still undergo repeat clinically indicated angiogra-
Figure 4. Rates of Subsequent TLR in Patients Who Were Treated Versus U
The untreated, intermediate lesion group tended to have more subsequent TLhy and intervention on significant restenosis or progressive tisease outside the stented segment, a strategy that would be
xpected to improve quality of life and subsequent event-
ree survival (31). Despite the nonstatistically significant
ifferences, it is interesting to note that the clinical-only
ollow-up group in the BMS cohort had numerically higher
ates of cardiac death and MI compared with the angio-
raphic follow-up group. The clinical-only follow-up group
ight have included some concealed restenosis, which
arallels a previously published report where restenosis was
ssociated with increased mortality in a BMS population
32). In contrast, patients with neither lifestyle-limiting
ngina nor objective evidence of significant myocardial
schemia do not benefit from the treatment of mild/
ntermediate coronary lesions, in terms of improved anginal
tatus, quality of life, or freedom from subsequent death or
I (4,7). In particular, stenoses 50% typically do not
mpede coronary flow reserve (33), and studies have consis-
ently shown that intermediate lesions with fractional flow
eserve of either 0.75 or 0.80 can safely have revascu-
arization deferred with similar (DEFER [Deferral Versus
erformance of PTCA in Patients Without Documented
schemia] trial) (8) or even decreased (FAME [Fractional
low Reserve Versus Angiography for Multivessel Evalua-
ion]) (9) adverse event rates compared with preemptive
evascularization. Importantly, these guidelines refer to
tenosis severity estimated by QCA rather than visual
stimation, which is known to overestimate stenosis severity
y 15% to 20% (34).
The present study has several important clinical implica-
ted at the Time of Follow-Up Angiography
reviations as in Figures 1 and 3.ntreaions. Routine angiographic follow-up, particularly if cou-
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410led with oculostenotic repeat revascularization of interme-
iate nonischemic lesions, increases health care expenses
ithout associated improvement in long-term prognosis,
ompared with clinical follow-up alone in which repeat
ngiography is reserved to evaluate recurrent symptoms or
bjective evidence of myocardial ischemia. Moreover, use of
outine angiographic follow-up can distort the results of
linical trials, especially when the temptation for oculoste-
otic reintervention is not well-controlled. Because roughly
ne-half of patients with angiographic restenosis (defined as
50% DS by QCA) have sufficiently severe restenosis
generally 70% DS by QCA) to cause recurrent ischemia,
ell-controlled trials generally show a “conversion rate”
rom binary angiographic restenosis to repeat TLR of
pproximately 50% (22–24,35,36). By contrast, some trials
ave reported conversion rates from angiographic restenosis
o TLR in excess of 70%, resulting in disparate results of
tent performance as reported from either pivotal trials or
arge registries (22–24,35–38). To avoid misleading results,
rotocol design should require stenosis 70% by QCA or
bjective evidence of ischemia as a threshold for performing
epeat revascularization (or considering a repeat revascular-
zation to be ischemia-driven).
This analysis has several important limitations. First, it is
post hoc analysis rather than a randomized controlled trial
omparing routine angiographic versus clinical-only follow-
p. Second, the 3 pooled trials differed slightly in their
nclusion/exclusion criteria, and the results from the
AXUS Express and Liberté stents in WH lesions were
ooled (39). Third, given that there was systematically
reater use of routine angiographic follow-up in the ana-
omically more complex TAXUS V study, it was necessary
o perform a secondary analysis selecting propensity-
atched angiographic and clinical follow-up groups, which
ight have failed to balance other unmeasured variables.
ourth, the statistical power was not sufficient to detect
mall differences between the angiographic and clinical-only
ollow-up groups for clinical end points other than TLR.
ifth, untreated patients with intermediate lesions at 9
onths were assumed to be ischemia-free, and no CEC
djudication for angina status was performed in patients
ho had not sustained a clinical event. Therefore, some
atients who exhibited ischemia at the time of the 9-month
ngiogram but were felt to be unsuitable for revasculariza-
ion might have been included in the group of untreated
atients. Finally, no long-term anginal status or quality of
ife data are available in these studies. Given these limita-
ions, this analysis should be considered hypothesis-
enerating rather than a definitive analysis of the value of
outine follow-up angiography after DES implantation, but
t certainly does not suggest any clinical benefit of routine
ngiographic follow-up in clinical practice.onclusions
he practice of routine angiographic follow-up after DES
mplantation leads to increased rates of repeat revascular-
zation via the oculostenotic treatment of mild to interme-
iate lesions. There is no evidence that either routine
ngiographic follow-up per se or the oculostenotic treat-
ent of such intermediate lesions provides any net clinical
enefit through 5 years of follow-up as compared with
linical follow-up only where angiography is reserved for
ecurrent symptoms or objective evidence of ischemia.
oreover, if angiographic follow-up is performed, leaving
symptomatic and nonischemia-producing intermediate le-
ions untreated poses no increased risk of death or MI and
an avoid the majority of repeat revascularizations.
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